Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : THE SLIGHTLY MODERATED BOXING RING -- Ignore unavailable to you. Want to Upgrade?

To: E who wrote (17383)	7/13/2002 6:53:04 PM
From: Lazarus_Long	Read Replies (1) \| Respond to of 21057

Some pediatric rheumatologists said, however, that methotrexate is not as risky and minocycline is not as safe for children as Trentham suggests. A cousin of tetracycline, it commonly is used to treat severe acne. But it can discolor teeth and skin, irritate the stomach, and, in rare instances, it can cause liver or kidney damage and has been associated with lupus. ...................................................................................................................................... 'We're able to control a large number of our patients with currently available drugs,'' said Edward Giannini of Cincinnati Children's Hospital, a senior scientist with an international consortium that studies pediatric rheumatology treatments and helped test Enbrel and methotrexate. ''I don't see much of a need to look at this drug, because we feel it's only partly effective in adults. But there's no harm in studying it.'' The situation is a bit more complicated than Trentham wants it to appear. Is he riding his pet hobby horse (antibiotics)? Probably. Is the drug company trying to block research on a competing drug? Probably. While companies have no legal obligation to support research by doctors who don't work for them, many scientists believe they have a moral responsibility to society. But they're not their companies and it's not their money. It's always easy to tell someone else what to do with their money. But don't be surprised if they ignore you and also don't appreciate it. ''Their interest is in their market share, not in public well-being.'' They're companies. They're businesses. They're not charities.